TG Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
TG Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
It's been a good week for TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders, because the company has just released its latest second-quarter results, and the shares gained 5.9% to US$20.04. In addition to beating expectations by 11% with revenues of US$73m, TG Therapeutics delivered a surprise (statutory) profit of US$0.04 per share, a sweet improvement compared to the losses that the analysts forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
tg therapeutics(納斯達克:TGTX)的股東們度過了愉快的一週,因爲公司剛剛發佈了最新的二季度業績報告,股價上漲了5.9%至20.04美元。除了營收達到7300萬美元,超出預期11%外,TG治療還實現了每股盈利0.04美元的驚喜利潤(來自法定報告)——較之分析師預測的虧損情況,這是一大進步。對於投資者而言,業績公告期是重要的時刻,他們可以追蹤公司的業績,了解分析師對明年的預測,感受機構投資者對公司態度的變化趨勢等等。因此,我們收集了最新的業績後預測,以了解分析師接下來對明年的預測。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240810/0-cd157cc31e79277d9f49badf0a772bf5-0-c913a2ec4ac34e4200418b6ff122872a.png/big)
Taking into account the latest results, the eight analysts covering TG Therapeutics provided consensus estimates of US$331.1m revenue in 2024, which would reflect a small 4.5% decline over the past 12 months. Statutory earnings per share are forecast to plunge 81% to US$0.13 in the same period. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$310.5m and losses of US$0.019 per share in 2024. The analysts have definitely been lifting their expectations, with the company expected to reach profitability next year - sooner than expected - thanks to the small lift in revenue expectations.
考慮到最新的業績結果,TG治療的八位分析師提供了2024年3.311億美元的營收共識預測,較過去12個月小幅下降4.5%。法定每股收益預計在同期下跌81%至0.13美元。然而,在最新的業績公告之前,分析師們預測的營收爲3.105億美元,預測每股虧損爲0.019美元。分析師顯然提高了預期,預計該公司由於營收預期的小幅提高而將在明年實現盈利–比預期要早–。
It will come as no surprise to learn that the analysts have increased their price target for TG Therapeutics 5.5% to US$33.38on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic TG Therapeutics analyst has a price target of US$49.00 per share, while the most pessimistic values it at US$8.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
毫不意外的是,根據這些升級的預測,分析師已將TG治療的目標股價上調5.5%至33.38美元。然而,另一種考慮股價目標的方式是觀察分析師提出的股價目標範圍,因爲廣泛的估值範圍可能表明業務未來可能存在多種觀點。最樂觀的TG治療分析師有49.00美元的股價目標,而最悲觀的TG治療分析師的目標只有8.00美元。可以看出,估值範圍很廣,最看好的預估小於最看跌的預估的一半,這表明分析師對機構的業績表現持有普遍不同的看法。因此,基於共識股價目標做出決策可能不是一個好主意,畢竟它只是這一估值範圍的平均值而已。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 8.8% by the end of 2024. This indicates a significant reduction from annual growth of 92% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 18% annually for the foreseeable future. It's pretty clear that TG Therapeutics' revenues are expected to perform substantially worse than the wider industry.
獲取更多背景信息的一種方法是,比較預測與過去表現以及其他同行業的公司的業績。這些預測表明,預計收入將放緩,到2024年底預計年化下降8.8%。這表明,同行業其他公司的收益在未來可預見的未來將以18%的年增長率增長。很明顯,TG治療的收入預期將比行業其他公司表現差得多。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that the analysts now expect TG Therapeutics to become profitable next year, compared to previous expectations that it would report a loss. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
最重要的一點是,分析師預計TG治療明年將實現盈利,而之前的預期是該公司將出現虧損。儘管預計增長速率會不如整個行業增長速率那麼快,他們還是提高了下年的營收預期。我們注意到,股價目標有升級跡象,這表明分析師認爲該公司的內在價值有望隨着時間的推移而提高。
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for TG Therapeutics going out to 2026, and you can see them free on our platform here..
沿着這種思路,我們認爲,公司的長期前景比明年的收益更爲相關。在Simply Wall St上,我們對TG治療的所有分析師預測一直持有全面的看法,預測延伸至2026年,您可以在我們的平台上免費查看。
And what about risks? Every company has them, and we've spotted 1 warning sign for TG Therapeutics you should know about.
那麼風險呢?每個公司都面臨着風險,我們已經發現TG治療存在1項警示信號,這是您應該知道的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。